Phase II Study to Evaluate the Effectiveness and Safety of Anlotinib Combined With Docetaxel in Progress After First Line Standard Cheomotherapy in Advanced Non-driver Mutation Non- Squamous Non-small Cell Lung Cancer
Who is this study for? Patients with advanced non-driver mutation non- squamous non-small cell lung cancer
What treatments are being studied? Anlotinib+Docetaxel
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• 18，Pathologically proven Non squamous non small cell lung cancer
‣ No-drive gene mutaion (EGFR、ALK、ROS1） by NGS
⁃ Progress after second line
⁃ PS score 0-2
Locations
Other Locations
China
Hunan Cancer Hospital
RECRUITING
Changsha
Contact Information
Primary
Yongchang Zhang, MD
yangnong0217@163.com
+8613873123436
Backup
Yongchang Zhang, MD
zhangyongchang@csu.edu.cn
+8613873123436
Time Frame
Start Date: 2018-08-01
Estimated Completion Date: 2025-06-01
Participants
Target number of participants: 43
Treatments
Experimental: Cohorts
Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer
Related Therapeutic Areas
Sponsors
Leads: Yongchang Zhang